NNVC
NanoViricides·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Stock Price Surged Significantly
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NNVC
Nanoviricides, Inc.
A company that developing therapeutics using nanomedicine technologies to treat viral infections
1 CONTROLS DRIVE, SHELTON, CONNECTICUT, 06484
--
NanoViricides, Inc., was incorporated in Nevada on April 1, 2005 and relocated to Delaware on May 30, 2023. The company is a clinical-stage company. The first drug is ready to enter the Phase II human clinical efficacy trial, and has successfully completed the Phase IA/IB human clinical safety and tolerability trials. They also have several additional drug candidates in various stages of preclinical development, including IND application stage and late-stage IND-supported non-clinical studies.
Company Financials
EPS
NNVC has released its 2026 Q1 earnings. EPS was reported at -0.1, versus the expected -0.18, beating expectations. The chart below visualizes how NNVC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
